Table 1 Patient demographics and genomic characteristics.
From: Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Baseline characteristic (N = 18) | N (%) |
|---|---|
Age at initiation of matched therapy (median), years | 67 (47–84) |
Sex | |
Male, N (%) | 7 (38.9%) |
Female, N (%) | 11 (61.1%) |
Race | |
White, N (%) | 15 (83.3%) |
Hispanic, N (%) | 1 (5.6%) |
Asian, N (%) | 1 (5.6%) |
Black, N (%) | 1 (5.6%) |
Extent of disease at diagnosis | |
Localized, N (%) | 6 (33.3%) |
Locally advanced, N (%) | 2 (11.1%) |
Metastatic, N (%) | 10 (55.6%) |
Extent of disease at time of matched therapy | |
Locally advanced, N (%) | 2 (11.1%) |
Metastatic, N (%) | 16 (88.9%) |
Number of prior therapies, median (range) | 1.5 (0–4) |
Matched therapy given as first-line therapy, N (%) | 5 (27.8%) |
Matched therapy given as second line or greater, N (%) | 13 (72.2%) |
Number of matched targeted agents, median (range) | 2.5 (1–4) |
Therapies given prior to matched treatment (N = 13), N (%) | |
Gemcitabine/nab-paclitaxel | 9 (50%) |
FOFLIRINOX | 6 (33.3%) |
Clinical Trial | 3 (16.7%) |
Capecitabine | 2 (11.1%) |
FOLFOX | 1 (5.6%) |
5-FU/liposomal irinotecan | 2 (11.1%) |
Gemcitabine/erlotinib | 1 (5.6%) |
Gemcitabine | 1 (5.6%) |
Genomic profiling | |
Tissue NGS obtained, N (%) | 15 (83.3%) |
Blood ctDNA obtained, N (%) | 14 (77.8%) |
Both ctDNA and tissue NGS obtained, N (%) | 11 (61.1%) |
Tissue NGS Platformsa (N = 15) | |
Foundation Oneb | 14 (77.8%) |
Tempusb | 1 (5.6%) |
Institutional Assay (UCSD) | 1 (5.6%) |
ctDNA Platforms (N = 14) | |
Guardant360 | 13 (72.2%) |
Tempus | 1 (5.6%) |
Matching score, median (range) | 50% (14–100%) |
